KYMR
Kymera Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$111.06-4.07%
Price as of Jul 20, 2026
KYMR valuation
Kymera Therapeutics, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 210.62x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 5.93x
- Price / sales
- 177.51x
- Price / cash flow
- -37.66x
Enterprise value
- Enterprise value
- $8.6B
- EV / sales
- 166.43x
- EV / EBITDA
- -27.99x
- EV / EBIT
- -23.85x
- Market cap
- $9.1B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.